In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on positive ...
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains and ...
WALTHAM, Mass. and BOULDER, Colo., June 14, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (COGT) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results